Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab Consolidation in Ovarian Cancer
NCT01246440Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Jun 2010
- Primary completion
- Feb 2014
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of catumaxomab in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Started Jun 2010; status: completed.
02
Drugs
catumaxomab
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01246440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01246440.